Immune Pharmaceuticals Inc (fka IMNPQ)

[Investor100]

IMNP Recap R & D

Alot going on here with R&D and of late we see alot of acquisitions....CEO bought a ton of stock in early 2016could we have one here....hmmm

https://finance.yahoo.com/news/immune-pharmaceuticals-provides-business-r-113000807.html

CEO keeps buying shares!

http://openinsider.com/search?q=imnp

NEW YORK, May 16, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP) ("Immune" or the "Company") announced financial results for the first quarter ended March 31, 2016.

Business and Research & Development ("R&D") Update

Immune continues to pursue its strategy to unlock the value of its diversified pipeline through the development, financing and strategic partnering of specifically focused asset groups:

Immuno-inflammation focus on gastro-enterology and dermatology through a pipeline comprised of two assets: bertilimumab, currently in two phase II clinical trials in ulcerative colitis and bullous pemphigoid with a third phase II planned in severe atopic dermatitis, and topical nano-formulated cyclosporine for the treatment of atopic dermatitis and psoriasis.
Immuno-oncology subsidiary that includes three mid-to-late stage clinical assets (Ceplene®, Azixa®, Crolibulin®) as well as novel platforms: bispecific antibodies and NanomAbs ®, antibody nanoparticle conjugates.
The licensing of AmiKet® and AmiKet® Nano for the treatment of peripheral neuropathic pain to a newly-created pain specialty pharma company:
Immune executed an exclusive 60-day option with Novel Pain Therapeutics ("NPT") to enter into a worldwide license agreement for AmiKet and AmiKet Nano for the treatment of peripheral neuropathic pain. Upon execution of the license agreement pursuant to agreed material terms in the option, NPT will assume all research and development costs and Immune will be eligible to receive up to $160 million, comprised of an upfront fee of at least $15 million in the form of equity in NPT, up to $25 million in development milestones, and up to $120 million in commercial milestones, as well as product sales royalties. Immune will also be eligible to receive 25% and up to 50% of sublicense fees received by NPT.

Immune continues to execute its R&D plan with progress for all its key assets:

Continued enrollment into the two Phase II clinical trials with bertilimumab.
Publication in Oncotarget and presentation at the American Academy of Cancer Research (AACR) meeting of European phase IV studies highlighting predictive bio-markers of overall survival in maintenance of first remission in patients with acute myeloid leukemia. Immune intends to submit to the Food and Drug Administration a plan for a pivotal overall survival study with Ceplene® in combination with low dose IL-2 (Proleukin®).
On-going development and testing of new bi-specific antibodies targeting PD-1 and OX40 (two immune check points) and PDL-1 and BCMA (an immune check point and a tumor marker of multiple myeloma).
On-going development of topical nano-formulated cyclosporine toward an investigational new drug application and initiation of 505(b) 2 clinical development.

"We are structuring the Company strategically to ensure long term comprehensive financing of our product pipeline and enable focused execution" said Dr. Daniel Teper, CEO of Immune Pharmaceuticals Inc. "We continue to progress in our clinical trials with bertilimumab as we increase patient enrollment and we are on track to achieve our operational and financial objectives for 2016."

Investor 100